Jacky Vonderscher

Company: ENYO Pharma

Job title: Co-Founder and Chief Executive Officer

Seminars:

Developing antifibrotic and anti-inflammatory therapeutics in clinical stage for common and rare renal diseases including CKD and Alport syndrome 11:30 am

Developing Vonafexor in the Proof-Of-Concept Phase 2 study “ALPESTRIA-1” in Alport syndrome Validating efficacy of Vonafexor on kidney function and kidney remodeling in a severe preclinical mouse model for CKD as much as for Alport syndrome Expanding Vonafexor analog development to larger kidney indicationsRead more

day: Day 2 Track 2 AM